Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 10:05AM ET
11.47
Dollar change
+0.40
Percentage change
3.57
%
IndexRUT P/E- EPS (ttm)-3.14 Insider Own34.70% Shs Outstand34.17M Perf Week-5.64%
Market Cap483.71M Forward P/E- EPS next Y-2.35 Insider Trans6.19% Shs Float27.55M Perf Month-14.38%
Income-108.30M PEG- EPS next Q-0.70 Inst Own60.41% Short Float17.85% Perf Quarter-4.78%
Sales0.00M P/S- EPS this Y9.73% Inst Trans2.83% Short Ratio6.22 Perf Half Y16.28%
Book/sh2.56 P/B4.48 EPS next Y21.93% ROA-68.23% Short Interest4.92M Perf Year68.36%
Cash/sh1.79 P/C6.40 EPS next 5Y- ROE-79.33% 52W Range6.60 - 16.88 Perf YTD-6.41%
Dividend Est.- P/FCF- EPS past 5Y-16.84% ROI-114.19% 52W High-32.08% Beta0.87
Dividend TTM- Quick Ratio5.44 Sales past 5Y-3.91% Gross Margin- 52W Low73.71% ATR (14)0.76
Dividend Ex-Date- Current Ratio5.44 EPS Y/Y TTM12.33% Oper. Margin0.00% RSI (14)38.52 Volatility5.51% 5.66%
Employees118 Debt/Eq0.08 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price31.60
Option/ShortYes / Yes LT Debt/Eq0.07 EPS Q/Q-10.98% Payout- Rel Volume13.21 Prev Close11.07
Sales Surprise- EPS Surprise-12.42% Sales Q/Q- EarningsMar 11 BMO Avg Volume791.01K Price11.47
SMA20-9.85% SMA50-15.28% SMA2006.65% Trades Volume1,413,819 Change3.57%
Date Action Analyst Rating Change Price Target Change
Jun-15-20Initiated H.C. Wainwright Buy $30
Jul-29-19Initiated SVB Leerink Outperform $31
Mar-20-19Initiated Needham Buy $35
Oct-30-18Initiated Jefferies Buy $30
Sep-21-18Initiated Cantor Fitzgerald Overweight
Aug-31-17Initiated BTIG Research Buy $18
Mar-18-24 06:30AM
Mar-12-24 06:30AM
Mar-11-24 06:30AM
Mar-08-24 06:30AM
Mar-07-24 06:30AM
06:30AM Loading…
Mar-06-24 06:30AM
Mar-04-24 06:30AM
Feb-27-24 06:30AM
Feb-26-24 06:30AM
Feb-20-24 06:30AM
Feb-16-24 06:30AM
Feb-15-24 06:30AM
Feb-14-24 04:18PM
Feb-13-24 07:10AM
06:40AM
06:30AM Loading…
06:30AM
01:30AM
Feb-02-24 06:30AM
Feb-01-24 12:02PM
Jan-13-24 03:12AM
Jan-12-24 03:03AM
Dec-30-23 09:02AM
Dec-29-23 06:45AM
Dec-20-23 06:30AM
Dec-07-23 04:49PM
06:30AM
Dec-05-23 06:30AM
Nov-23-23 05:14AM
Nov-22-23 05:04AM
Nov-14-23 10:31PM
06:30AM Loading…
06:30AM
Nov-13-23 06:30AM
Nov-07-23 06:30AM
Nov-03-23 06:30AM
Nov-02-23 06:30AM
Oct-30-23 09:32AM
Oct-25-23 09:40AM
Oct-24-23 06:30AM
Oct-09-23 09:40AM
Oct-03-23 06:30AM
Sep-20-23 09:02AM
Sep-19-23 06:30AM
Sep-18-23 08:52AM
Sep-14-23 01:04AM
Sep-07-23 06:30AM
Sep-06-23 09:40AM
Aug-28-23 06:30AM
Aug-02-23 04:15PM
Jul-25-23 06:30AM
Jul-24-23 06:30AM
Jul-14-23 06:30AM
Jul-10-23 09:54AM
Jul-07-23 06:30AM
Jul-05-23 06:30AM
Jun-12-23 06:30AM
Jun-05-23 06:30AM
Jun-02-23 06:30AM
May-31-23 06:30AM
May-23-23 06:30AM
May-08-23 06:30AM
May-02-23 06:30AM
Apr-27-23 06:30AM
Apr-20-23 09:55AM
Apr-19-23 12:53PM
Apr-12-23 11:06AM
06:30AM
Apr-11-23 08:57AM
Apr-10-23 10:07AM
Apr-04-23 09:55AM
Mar-22-23 09:55AM
Mar-09-23 06:30AM
Mar-03-23 09:55AM
Feb-27-23 06:30AM
Feb-16-23 06:30AM
Feb-14-23 06:30AM
Feb-10-23 06:30AM
Feb-07-23 12:00PM
09:55AM
06:30AM
Feb-03-23 06:30AM
Feb-02-23 06:30AM
Jan-05-23 06:30AM
Jan-04-23 06:30AM
Dec-30-22 06:48AM
Dec-27-22 06:30AM
Dec-08-22 06:30AM
Dec-05-22 07:00AM
Nov-14-22 06:45AM
Nov-10-22 09:53AM
Nov-07-22 06:45AM
Nov-02-22 07:00AM
Oct-31-22 11:00AM
06:45AM
Oct-19-22 06:45AM
Oct-17-22 06:45AM
Oct-10-22 07:58PM
Oct-07-22 04:15PM
Oct-06-22 01:50PM
10:28AM
Oct-05-22 07:00AM
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Feener Edward P.CHIEF SCIENTIFIC OFFICERFeb 20 '24Sale14.0728,288397,92962,157Feb 21 09:51 PM
Crockett Thomas AndrewCEOFeb 20 '24Sale14.1124,888351,289211,203Feb 21 09:41 PM
Palleiko Benjamin LCFO, CBOFeb 20 '24Sale14.1122,802321,846187,315Feb 21 09:46 PM
Audhya Paul K.CHIEF MEDICAL OFFICERFeb 20 '24Sale14.1214,295201,77452,886Feb 21 09:44 PM
Yea ChristopherCHIEF DEVELOPMENT OFFICERFeb 20 '24Sale14.1112,053170,12472,895Feb 21 09:48 PM
Crockett Thomas AndrewCEOFeb 14 '24Sale15.0158,356875,883181,676Feb 16 04:20 PM
Palleiko Benjamin LCFO, CBOFeb 14 '24Sale15.0140,855613,205159,088Feb 16 04:21 PM
Yea ChristopherCHIEF DEVELOPMENT OFFICERFeb 14 '24Sale15.0139,886598,66166,160Feb 16 04:18 PM
Feener Edward P.CHIEF SCIENTIFIC OFFICERFeb 14 '24Sale15.0128,171422,82771,657Feb 16 04:19 PM
Venrock Healthcare Capital Par10% OwnerFeb 08 '24Buy14.7029,747437,2814,824,731Feb 08 08:11 PM
Venrock Healthcare Capital Par10% OwnerFeb 07 '24Buy14.5651,827754,6014,794,984Feb 08 08:11 PM
Venrock Healthcare Capital Par10% OwnerFeb 06 '24Buy14.744,47465,9474,743,157Feb 08 08:11 PM
Crockett Thomas AndrewCEOFeb 01 '24Sale16.2210,000162,198117,532Feb 05 05:55 PM
Venrock Healthcare Capital Par10% OwnerJan 30 '24Buy14.4788,0991,274,7934,738,683Feb 01 04:38 PM
Venrock Healthcare Capital Par10% OwnerJan 29 '24Buy14.2280,6001,146,1324,650,584Jan 29 07:07 PM
Venrock Healthcare Capital Par10% OwnerJan 26 '24Buy12.984,17454,1794,569,984Jan 29 07:07 PM
Venrock Healthcare Capital Par10% OwnerJan 25 '24Buy12.737,03089,4924,565,810Jan 29 07:07 PM
Venrock Healthcare Capital Par10% OwnerJan 24 '24Buy12.4420,686257,3344,558,780Jan 24 08:24 PM
Venrock Healthcare Capital Par10% OwnerJan 23 '24Buy12.5410,897136,6484,538,094Jan 24 08:24 PM
Venrock Healthcare Capital Par10% OwnerJan 22 '24Buy12.5567,546847,7024,527,197Jan 24 08:24 PM
Venrock Healthcare Capital Par10% OwnerJan 19 '24Buy12.4325,000310,7504,459,651Jan 19 06:02 PM
Venrock Healthcare Capital Par10% OwnerJan 18 '24Buy12.5139,680496,3974,434,651Jan 19 06:02 PM
Venrock Healthcare Capital Par10% OwnerJan 17 '24Buy12.6078,925994,4554,394,971Jan 19 06:02 PM
Venrock Healthcare Capital Par10% OwnerJan 16 '24Buy12.7319,599249,4954,316,046Jan 16 07:04 PM
Venrock Healthcare Capital Par10% OwnerJan 11 '24Buy12.686,64784,2844,296,447Jan 16 07:04 PM
Feener Edward P.Chief Scientific OfficerJan 11 '24Sale13.0322,679295,51439,828Jan 12 04:26 PM
Venrock Healthcare Capital Par10% OwnerJan 10 '24Buy12.6747,700604,3594,289,800Jan 10 08:57 PM
Venrock Healthcare Capital Par10% OwnerJan 09 '24Buy12.5620,816261,4494,242,100Jan 10 08:57 PM
Feener Edward P.Chief Scientific OfficerJan 09 '24Sale13.001001,30062,507Jan 10 06:05 PM
Venrock Healthcare Capital Par10% OwnerJan 08 '24Buy12.4469,184860,6494,221,284Jan 10 08:57 PM
Feener Edward P.Chief Scientific OfficerJan 08 '24Sale13.0117,221224,00062,607Jan 10 06:05 PM
Venrock Healthcare Capital Par10% OwnerJan 04 '24Buy12.1141,764505,7624,152,100Jan 05 04:13 PM
Venrock Healthcare Capital Par10% OwnerJan 03 '24Buy12.2017,605214,7814,110,336Jan 05 04:13 PM
Venrock Healthcare Capital Par10% OwnerDec 29 '23Buy12.496,01375,1024,092,731Dec 29 06:44 PM
Venrock Healthcare Capital Par10% OwnerDec 28 '23Buy12.50471,4905,893,6254,086,718Dec 29 06:44 PM
Venrock Healthcare Capital Par10% OwnerDec 27 '23Buy11.9741,514496,9233,615,228Dec 29 06:44 PM
Crockett Thomas AndrewCEODec 27 '23Sale12.0230,000360,453127,532Dec 28 04:28 PM
Crockett Thomas AndrewCEONov 20 '23Sale8.2314,807121,851157,532Nov 21 04:30 PM
Palleiko Benjamin LPresident, CFO, CBO & Sec'yNov 20 '23Sale8.2313,008107,047112,443Nov 21 04:31 PM
Audhya Paul K.Chief Medical OfficerNov 20 '23Sale8.237,98565,71136,568Nov 21 04:34 PM
Yea ChristopherChief Development OfficerNov 20 '23Sale8.237,11358,53546,046Nov 21 04:32 PM
Feener Edward P.Chief Scientific OfficerNov 20 '23Sale8.234,95840,80179,828Nov 21 04:33 PM
Cha AlbertDirectorSep 11 '23Option Exercise7.4918,000134,82018,000Sep 13 04:29 PM
Cha AlbertDirectorSep 11 '23Sale10.5018,000189,0500Sep 13 04:29 PM
Crockett Thomas AndrewCEOAug 18 '23Sale10.7314,876159,602146,756Aug 21 08:05 PM
Palleiko Benjamin LPresident, CFO, CBO & Sec'yAug 18 '23Sale10.7313,067140,19295,254Aug 21 08:05 PM
Audhya Paul K.Chief Medical OfficerAug 18 '23Sale10.738,02086,04526,023Aug 21 08:09 PM
Yea ChristopherChief Development OfficerAug 18 '23Sale10.737,14276,62441,662Aug 21 08:06 PM
Feener Edward P.Chief Scientific OfficerAug 18 '23Sale10.734,97653,38673,289Aug 21 08:07 PM
Crockett Thomas AndrewCEOMay 18 '23Sale10.145,62757,083128,050May 19 09:17 PM
Palleiko Benjamin LPresident, CFO, CBO & Sec'yMay 18 '23Sale10.144,03740,95378,126May 19 09:19 PM
Audhya Paul K.Chief Medical OfficerMay 18 '23Sale10.142,78028,20113,014May 19 09:16 PM
Yea ChristopherChief Development OfficerMay 18 '23Sale10.142,60426,41637,310May 19 09:20 PM
Feener Edward P.Chief Scientific OfficerMay 18 '23Sale10.141,78618,11866,771May 19 09:18 PM